SEC Form 4

1 17

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person

STATEMEN

Filed p

2.

N

01/25/2022

T OF CHANGES IN BENEFICIAL OWNE	RSHIP	hours per response: 0.5			
oursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940					
Issuer Name and Ticker or Trading Symbol IARAVAI LIFESCIENCES HOLDINGS,	5. Relationship of Rep (Check all applicable)	porting Person(s) to Issuer			

OMB APPROVAL

3235-0287

OMB Number

Estimated ave

				[MRVI]			HOLDIN		Director Officer (give title	10% O	wner specify	
(Last) (First) (Middle) C/O MARAVAI LIFESCIENCES HOLDINGS, INC.				f Earliest Transaction 022	on (Mon	th/Day	/Year)		below) below) Chief Financial Officer			
10770 WATERIE	OGE CIRCI	LE, SUITE 200	4. If Ame	ndment, Date of Or	iginal Fi	led (Mo	onth/Day/Year)		6. Indiv	idual or Joint/Group Fi Form filed by One I		able Line)
(Street) SAN DIEGO	СА	92121								Form filed by More		ng Person
(City)	(State)	(Zip)										
		Table I - Nor	n-Derivative S	Securities Acq	uired,	Disp	osed of, o	r Benefi	cially Ow	vned		
1. Title of Security (Instr. 3) 2. Tran Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (I 8)		4. Securities A Disposed Of (5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
SAN DIEGO CA 92121 (City) (State) (Zip) Table I - Nor 1. Title of Security (Instr. 3) Class A Common Stock					v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(Instr. 4)	
Class A Common	Stock		04/30/2021		Α	V ⁽¹⁾	497	A	\$22.95	497	D	
Class A Common	Stock		10/31/2021		Α	V ⁽¹⁾	392	Α	\$22.95	889	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

Α

19,500

Α

(2)

20,389

D

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (Right to Buy)	\$26.32	01/25/2022		A		36,200		(3)	01/25/2032	Class A Common Stock	36,200	\$0.00	36,200	D	

Explanation of Responses:

Class A Common Stock

1. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 889 shares of Class A Common Stock was also exempt pursuant to Rule 16b-3(c).

2. Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the reporting person's continued employment with the Issuer.

3. Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

/s/ Kurt Oreshack, by power of attorney for Kevin Herde ** Signature of Reporting Person

01/27/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.